Stock ALBPS BIOPHYTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biophytis S.A.

Equities

ALBPS

FR001400OLP5

Real-time Euronext Paris
Other stock markets
 08:10:25 2024-07-12 am EDT 		5-day change 1st Jan Change
0.575 EUR 0.00% Intraday chart for Biophytis S.A. -0.86% -71.81%
10:02am BIOPHYTIS : Invest Securities confirms its recommendation CF
Jul. 11 Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BIOPHYTIS : Invest Securities confirms its recommendation
CF
Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug
MT
Biophytis: approval for a clinical trial in the USA
CF
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity
CI
Biophytis S A : obtains IND approval from the FDA to start its phase 2 OBA study in obesity
PU
Biophytis S A : obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
PU
BIOPHYTIS PRESENTED ITS PHASE 2-3 COVA STUDY RESULTS IN SEVERE FORMS OF COVID-19 AT THE WCID IN PARIS
AQ
Biophytis SA Presents Roll-Out and Results of Its Phase 2-3 Cova Study Results in Severe Forms of Covid-19 At the World Congress on Infectious Diseases
CI
Biophytis S A : RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 Form 6 K
PU
Biophytis S A : RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
PU
Biophytis S A : RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 24 JUIN 2024
PU
Biophytis: cash position strengthened, share price soars
CF
Biophytis Extends Bond Financing Deal with Investment Fund Atlas
MT
Biophytis S.A. Grants Blanver Exclusive Rights to Bio101 in Latin America in Deal Valued At Up to ?108 Million
CI
Biophytis S A : grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
PU
Biophytis S A : accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€
PU
Biophytis S A : extends its contract with Atlas to secure financing for its business activities
PU
Biophytis S A : prolonge son contrat avec Atlas pour sécuriser le financement de ses activités
PU
Biophytis S.A. Announces the Successful Industrial Transfer of Bio101 (20-Hydroxyecdysone) Production by Its Service Provider Seqens
CI
Biophytis S A : annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALBPS Stock
  4. News Biophytis S.A.